|
시장보고서
상품코드
1890928
유전자 벡터 시장 : 벡터 유형별, 페이로드 유형별, 용도별, 질환 영역별, 전달 경로별, 전달 모드별, 최종사용자별, 지역별Gene Vector Market, By Vector Type, By Payload Type, By Application, By Disease Area, By Delivery Route, By Delivery Mode, By End User, By Geography |
||||||
유전자 벡터 시장은 2025년에 93억 5,000만 달러로 추정되며, 2032년까지 215억 9,000만 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 12.7%로 성장할 것으로 전망되고 있습니다.
| 리포트 내용 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 93억 5,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 12.70% | 2032년 예측 : | 215억 9,000만 달러 |
세계 유전자 벡터 시장은 생명공학 및 제약 산업에서 중요한 분야로, 다양한 질병을 치료하기 위해 치료용 유전 물질을 표적 세포로 운반하도록 설계된 첨단 전달 시스템을 포함합니다. 유전자 벡터는 DNA, RNA, 기타 핵산을 포함한 유전 물질을 환자 세포에 도입하여 유전적 결함을 교정하거나 면역 반응을 강화하거나 치료용 단백질을 제공할 수 있는 매개체 역할을 합니다.
본 시장은 바이러스성 벡터(아데노바이러스, 렌치바이러스, 레트로바이러스, 아데노연관바이러스), 비바이러스성 벡터(리포펙션, 일렉트로포레이션, 마이크로인젝션) 및 신흥 하이브리드 시스템 등 다양한 벡터 유형을 포함합니다. 유전성 질환, 암, 희귀질환의 유병률이 증가함에 따라 혁신적인 유전자 치료 솔루션에 대한 수요가 크게 증가하고 있으며, 유전자 벡터는 맞춤형 의료 접근법의 중요한 구성 요소로 자리매김하고 있습니다.
유전자 치료 연구에 대한 투자 증가, 유전자 치료의 규제 승인, 벡터 공학의 기술 발전으로 인해 시장은 괄목할 만한 성장세를 보이고 있습니다. 주요 제약사, 생명공학 기업, 연구기관들은 전달 효율 향상, 면역원성 감소, 치료 효과 강화를 위한 신규 벡터 시스템 개발을 적극적으로 추진하고 있으며, 이를 통해 종양학, 안과학, 면역학, 희귀질환 치료 분야에서 시장의 잠재적 가능성이 확대되고 있습니다.
시장 역학
세계 유전자 벡터 시장은 유전자 질환 및 암 발생률 증가와 같은 여러 주요 촉진요인에 의해 주도되고 있습니다. 이들은 유전자 벡터가 제공할 수 있는 혁신적인 치료 접근법을 필요로 합니다. 유전자 치료 연구개발에 대한 막대한 투자와 더불어 정부 자금과 벤처캐피털 투자 증가가 시장 성장을 가속화하고 있습니다.
유전자치료제 임상시험 건수 증가, 미국 FDA의 각종 유전자치료제 승인 등 최근 규제당국의 승인은 시장에 호재로 작용하고 있습니다. 표적 특이성 향상, 면역원성 감소 등 벡터 공학의 기술적 진보는 치료 효과와 환자 안전성 프로파일을 향상시키고 있습니다. 그러나 시장에는 큰 제약도 존재합니다. 주로 유전자 벡터의 개발 및 제조에 따른 높은 비용이 접근성과 상업적 타당성을 제한하고 있습니다.
복잡한 규제 요건과 길어지는 승인 절차는 시장 진입과 제품 상용화에 걸림돌이 되고 있습니다. 바이러스 벡터에 의한 면역 반응, 잠재적 삽입성 돌연변이 유발, 장기적 영향에 대한 안전성 우려는 시장 수용의 장벽으로 남아있습니다. 또한 페이로드 용량의 제한, 조직 특이적 표적화의 어려움 등 벡터 설계상의 기술적 문제도 치료 적용을 제한하고 있습니다. 그러나 시장 상황에는 여전히 큰 기회가 존재합니다.
치료 옵션이 제한적인 희귀질환 치료에서 유전자 벡터의 적용 확대는 수익성 높은 성장 가능성을 보여주고 있습니다. 아시아태평양과 라틴아메리카의 신흥 시장에서는 의료 인프라의 개선과 인지도 향상으로 미개발 가능성이 확대되고 있습니다. 제약회사와 바이오테크놀러지 기업과의 협업 파트너십은 혁신과 시장 확대를 촉진하고 있습니다. 안전성 프로파일을 개선하고 전달 능력을 향상시킨 차세대 벡터의 개발과 제조 비용 절감을 기대할 수 있는 제조 기술의 발전은 시장 진출기업에게 중요한 성장 기회가 될 것입니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR)을 나타내는 세계 유전자 벡터 시장에 대한 상세한 분석 정보를 제공합니다.
- 이 보고서에서는 다양한 부문의 잠재적 매출기회를 확인하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 유전자 벡터 시장의 주요 기업을 프로파일링합니다.
- 이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 유전자 벡터 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 유전자 벡터 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 유전자 벡터 시장 : 벡터 유형별, 2020-2032년
- 바이러스 벡터
- 비바이러스성 벡터
제5장 세계의 유전자 벡터 시장 : 페이로드 유형별, 2020-2032년
- DNA 벡터
- RNA 벡터
- siRNA/shRNA 벡터
- CRISPR/Cas 컴포넌트
- 안티센스 올리고뉴클레오티드
- mRNA 벡터
제6장 세계의 유전자 벡터 시장 : 용도별, 2020-2032년
- 유전자 치환 요법
- 유전자 추가·증강 요법
- 유전자 침묵/넉다운
- 유전자 편집(CRISPR, ZFN, TALEN)
- 세포치료 제조(CAR-T, 개변 NK/T세포)
- 백신(예방용 및 치료 용)
- 연구용 전용(전임상 시험용 in vitro/in vivo 툴)
제7장 세계의 유전자 벡터 시장 : 질환 영역별, 2020-2032년
- 종양학
- 신경학
- 순환기·대사질환
- 안과
- 혈액·면역학
- 감염증
- 근골격계 및 유전성관계 질환
- 피부과 및 창상 치유
- 기타 희소 유전성 질환
제8장 세계의 유전자 벡터 시장 : 전달 경로별, 2020-2032년
- 정맥내 투여
- 근육내
- 피하
- 척수강내
- 종양내 투여
- 안내
- 흡입
- 기타
제9장 세계의 유전자 벡터 시장 : 전달 모드별, 2020-2032년
- 생체내 전달
- 체외 전달
제10장 세계의 유전자 벡터 시장 : 최종사용자별, 2020-2032년
- 바이오의약품·바이오테크놀러지 기업
- CDMO/CMO(수탁 개발 제조 기관)
- 학술·연구기관
- 정부 및 비영리 연구기관
- 병원내 및 전문 유전자 치료 센터
제11장 세계의 유전자 벡터 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Lonza Group
- Thermo Fisher Scientific
- Catalent Inc
- Oxford Biomedica
- FUJIFILM Diosynth Biotechnologies
- Advanced Therapies, LLC.
- Aldevron
- AGC Biologics
- SIRION Biotech
- FinVector
- Merck KGaA
- uniQure
- Charles River Laboratories
- Takara Bio
제13장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Gene Vector Market is estimated to be valued at USD 9.35 Bn in 2025 and is expected to reach USD 21.59 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 9.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.70% | 2032 Value Projection: | USD 21.59 Bn |
The global gene vector market represents a pivotal segment within the biotechnology and pharmaceutical industries, encompassing sophisticated delivery systems designed to transport therapeutic genetic material into target cells for treatment of various diseases. Gene vectors serve as vehicles that facilitate the introduction of genetic material, including DNA, RNA, and other nucleic acids, into patient cells to correct genetic defects, enhance immune responses, or provide therapeutic proteins.
This market encompasses various vector types including viral vectors (adenovirus, lentivirus, retrovirus, adeno-associated virus), non-viral vectors (lipofection, electroporation, microinjection), and emerging hybrid systems. The growing prevalence of genetic disorders, cancer, and rare diseases has significantly amplified the demand for innovative gene therapy solutions, positioning gene vectors as critical components in personalized medicine approaches.
The market has witnessed substantial growth driven by increasing investments in gene therapy research, regulatory approvals for gene-based treatments, and technological advancements in vector engineering. Major pharmaceutical companies, biotechnology firms, and research institutions are actively developing novel vector systems to improve delivery efficiency, reduce immunogenicity, and enhance therapeutic outcomes, thereby expanding the market's potential across oncology, ophthalmology, immunology, and rare disease applications.
Market Dynamics
The global gene vector market is propelled by several key drivers, including the rising incidence of genetic disorders and cancer worldwide, which necessitates innovative therapeutic approaches that gene vectors can provide. Substantial investments in gene therapy research and development, coupled with increasing government funding and venture capital investments, are accelerating market growth.
The growing number of clinical trials for gene therapies and recent regulatory approvals, such as U.S. FDA approvals for various gene therapy products, have created favorable market conditions. Technological advancements in vector engineering, including improved targeting specificity and reduced immunogenicity, are enhancing therapeutic efficacy and patient safety profiles. However, the market faces significant restraints, primarily the high costs associated with gene vector development and manufacturing, which limit accessibility and commercial viability.
Complex regulatory requirements and lengthy approval processes create barriers for market entry and product commercialization. Safety concerns related to viral vector-induced immune responses, potential insertional mutagenesis, and long-term effects continue to challenge market acceptance. Additionally, technical challenges in vector design, including limited payload capacity and tissue-specific targeting difficulties, restrict therapeutic applications. Nevertheless, substantial opportunities exist within the market landscape.
The expanding applications of gene vectors in treating rare diseases, where limited therapeutic options exist, present lucrative growth prospects. Emerging markets in Asia Pacific and Latin America offer untapped potential due to improving healthcare infrastructure and increasing awareness. Collaborative partnerships between pharmaceutical companies and biotechnology firms are fostering innovation and market expansion. The development of next-generation vectors with improved safety profiles and enhanced delivery capabilities, along with advances in manufacturing technologies that could reduce production costs, represent significant growth opportunities for market participants.
Key Features of the Study
- This report provides in-depth analysis of the global gene vector market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global gene vector market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Lonza Group, Thermo Fisher Scientific, Catalent Inc, Oxford Biomedica, FUJIFILM Diosynth Biotechnologies, Advanced Therapies, LLC., Aldevron, AGC Biologics, SIRION Biotech, FinVector, Merck KGaA, uniQure, Charles River Laboratories, Takara Bio.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global gene vector market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene vector market
Market Segmentation
- Vector Type Insights (Revenue, USD Bn, 2020 - 2032)
- Viral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral (AAV) Vectors
- Lentiviral Vectors
- Gamma-Retroviral Vectors
- Herpes Simplex Viral (HSV) Vectors
- Poxviral/Vaccinia Vectors
- Other Viral Vectors (Sendai, VSV, Baculovirus, etc.)
- Non-Viral Vectors
- Plasmid DNA Vectors
- Lipid-Based Nanoparticle (LNP) Vectors
- Polymeric/Synthetic Nanoparticle Vectors
- Inorganic Nanoparticle Vectors (gold, silica-based, etc.)
- Payload Type Insights (Revenue, USD Bn, 2020 - 2032)
- DNA Vectors
- RNA Vectors
- siRNA/shRNA Vectors
- CRISPR/Cas Components
- Antisense Oligonucleotides
- mRNA Vectors
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Gene Replacement Therapy
- Gene Addition/Augmentation Therapy
- Gene Silencing/Knockdown
- Gene Editing (CRISPR, ZFN, TALEN)
- Cell Therapy Manufacturing (CAR-T, engineered NK/T cells)
- Vaccines (prophylactic and therapeutic)
- Research Use Only (preclinical in vitro/in vivo tools)
- Disease Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Neurology
- Cardiovascular and Metabolic
- Ophthalmic
- Hematologic and Immunologic
- Infectious Diseases
- Musculoskeletal and Genetic Muscle Disorders
- Dermatology and Wound Healing
- Other Rare Genetic Disorders
- Delivery Route Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Intramuscular
- Subcutaneous
- Intrathecal
- Intratumoral
- Ocular
- Inhalation
- Others
- Delivery Mode Insights (Revenue, USD Bn, 2020 - 2032)
- In Vivo Delivery
- Ex Vivo Delivery
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Biopharmaceutical and Biotechnology Companies
- CDMOs/CMOs (Contract Development and Manufacturing Organizations)
- Academic and Research Institutes
- Government and Non-Profit Research Organizations
- Hospital-Based and Specialty Gene Therapy Centers
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Lonza Group
- Thermo Fisher Scientific
- Catalent Inc
- Oxford Biomedica
- FUJIFILM Diosynth Biotechnologies
- Advanced Therapies, LLC.
- Aldevron
- AGC Biologics
- SIRION Biotech
- FinVector
- Merck KGaA
- uniQure
- Charles River Laboratories
- Takara Bio
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gene Vector Market, By Vector Type
- Global Gene Vector Market, By Payload Type
- Global Gene Vector Market, By Application
- Global Gene Vector Market, By Disease Area
- Global Gene Vector Market, By Delivery Route
- Global Gene Vector Market, By Delivery Mode
- Global Gene Vector Market, By End User
- Global Gene Vector Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Gene Vector Market, By Vector Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Viral Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adenoviral Vectors
- Adeno-Associated Viral (AAV) Vectors
- Lentiviral Vectors
- Gamma-Retroviral Vectors
- Herpes Simplex Viral (HSV) Vectors
- Poxviral/Vaccinia Vectors
- Other Viral Vectors (Sendai, VSV, Baculovirus, etc.)
- Non-Viral Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Plasmid DNA Vectors
- Lipid-Based Nanoparticle (LNP) Vectors
- Polymeric/Synthetic Nanoparticle Vectors
- Inorganic Nanoparticle Vectors (gold, silica-based, etc.)
5. Global Gene Vector Market, By Payload Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- DNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- RNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- siRNA/shRNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- CRISPR/Cas Components
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antisense Oligonucleotides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- mRNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Gene Vector Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gene Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gene Addition/Augmentation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gene Silencing/Knockdown
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gene Editing (CRISPR, ZFN, TALEN)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cell Therapy Manufacturing (CAR-T, engineered NK/T cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Vaccines (prophylactic and therapeutic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research Use Only (preclinical in vitro/in vivo tools)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Gene Vector Market, By Disease Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular and Metabolic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hematologic and Immunologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Musculoskeletal and Genetic Muscle Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dermatology and Wound Healing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Gene Vector Market, By Delivery Route, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intrathecal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intratumoral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ocular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Gene Vector Market, By Delivery Mode, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- In Vivo Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ex Vivo Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Gene Vector Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Biopharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- CDMOs/CMOs (Contract Development and Manufacturing Organizations)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Government and Non-Profit Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital-Based and Specialty Gene Therapy Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Gene Vector Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vector Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Catalent Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Oxford Biomedica
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Diosynth Biotechnologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced Therapies, LLC.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aldevron
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AGC Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- SIRION Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FinVector
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Charles River Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takara Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
